gabexate and gemcitabine

gabexate has been researched along with gemcitabine in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Biasco, G; Brandi, G; De Rosa, F; Di Girolamo, S; Di Marco, M; Guarnieri, T; Macchini, M; Papi, A; Paterini, P; Tavolari, S	1

Other Studies

2 other study(ies) available for gabexate and gemcitabine

Article	Year
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study. Pancreas, 2014, Volume: 43, Issue:1 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Evaluation, Preclinical; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gabexate; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Serine Proteinase Inhibitors; Vascular Endothelial Growth Factor A	2014

Article

Year

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.

Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023

Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.

Pancreas, 2014, Volume: 43, Issue:1

Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Evaluation, Preclinical; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gabexate; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Serine Proteinase Inhibitors; Vascular Endothelial Growth Factor A

2014